AR082608A1 - Formas solidas de clorhidrato de 4-[2-[[5-metil-1-(2-naftalenil)-1h-pirazol-3-il]oxi]etil]morfolina - Google Patents

Formas solidas de clorhidrato de 4-[2-[[5-metil-1-(2-naftalenil)-1h-pirazol-3-il]oxi]etil]morfolina

Info

Publication number
AR082608A1
AR082608A1 ARP110102890A ARP110102890A AR082608A1 AR 082608 A1 AR082608 A1 AR 082608A1 AR P110102890 A ARP110102890 A AR P110102890A AR P110102890 A ARP110102890 A AR P110102890A AR 082608 A1 AR082608 A1 AR 082608A1
Authority
AR
Argentina
Prior art keywords
methyl
solid forms
naftalenyl
pirazol
etil
Prior art date
Application number
ARP110102890A
Other languages
English (en)
Inventor
Fernandez Laura Puig
Buchholz Jordi Benet
Original Assignee
Esteve Labor Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esteve Labor Dr filed Critical Esteve Labor Dr
Publication of AR082608A1 publication Critical patent/AR082608A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18One oxygen or sulfur atom
    • C07D231/20One oxygen atom attached in position 3 or 5
    • C07D231/22One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente solicitud se refiere a formas sólidas que tienen un bajo grado de cristalinidad (el grado de cristalinidad es inferior al 3%) o sustancialmente amorfas de la sal de clorhidrato de 4-[2-[[5-metil-1-(2-naftalenil)-1H-pirazol-3-il]oxi]etil]morfina (P027), y a procedimientos para su preparación. Útil en enfermedades del SNC.Reivindicación 3: Forma sólida según la reivindicación 2, que tiene un espectro de FTIR que muestra picos característicos a aproximadamente: 3421, 3137, 3054, 2959, 2859, 2540, 2447, 1632, 1600, 1557, 1509, 1487, 1442, 1372, 1305, 1290, 1256, 1236, 1199, 1169, 1130, 1100, 1046, 1013, 982, 933, 917, 861, 819 y 748 cm-1.
ARP110102890A 2010-08-09 2011-08-09 Formas solidas de clorhidrato de 4-[2-[[5-metil-1-(2-naftalenil)-1h-pirazol-3-il]oxi]etil]morfolina AR082608A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10382225A EP2426111A1 (en) 2010-08-09 2010-08-09 4-[-2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride amorphous solid forms

Publications (1)

Publication Number Publication Date
AR082608A1 true AR082608A1 (es) 2012-12-19

Family

ID=43244877

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110102890A AR082608A1 (es) 2010-08-09 2011-08-09 Formas solidas de clorhidrato de 4-[2-[[5-metil-1-(2-naftalenil)-1h-pirazol-3-il]oxi]etil]morfolina

Country Status (19)

Country Link
US (1) US9428462B2 (es)
EP (2) EP2426111A1 (es)
JP (1) JP5899214B2 (es)
KR (1) KR20130095751A (es)
CN (1) CN103052626B (es)
AR (1) AR082608A1 (es)
AU (1) AU2011288550A1 (es)
BR (1) BR112013002651A2 (es)
CA (1) CA2807855C (es)
CO (1) CO6670586A2 (es)
ES (1) ES2543429T3 (es)
HK (1) HK1186468A1 (es)
MA (1) MA34512B1 (es)
MX (1) MX341711B (es)
PT (1) PT2603495E (es)
RU (1) RU2013110313A (es)
SG (1) SG187745A1 (es)
TW (1) TW201219387A (es)
WO (1) WO2012019984A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2116539A1 (en) 2008-04-25 2009-11-11 Laboratorios Del. Dr. Esteve, S.A. 1-aryl-3-aminoalkoxy-pyrazoles as sigma ligands enhancing analgesic effects of opioids and attenuating the dependency thereof
EP2353591A1 (en) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof
EP2353598A1 (en) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for use in the prevention and/or treatment of postoperative pain
EP2388005A1 (en) 2010-05-21 2011-11-23 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy
EP2415471A1 (en) 2010-08-03 2012-02-08 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in opioid-induced hyperalgesia
EP2524694A1 (en) 2011-05-19 2012-11-21 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in diabetes type-2 associated pain
EP2792352A1 (en) 2013-04-16 2014-10-22 Laboratorios Del. Dr. Esteve, S.A. Alpha-2 adrenoreceptor and sigma receptor ligand combinations
MX2016007286A (es) 2013-12-17 2016-08-04 Esteve Labor Dr Combinaciones de gabapentinoides y ligandos de receptores sigma.
AU2014364647A1 (en) 2013-12-17 2016-06-23 Laboratorios Del Dr. Esteve, S.A. Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) and Sigma receptor ligands combinations

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04364129A (ja) * 1990-10-26 1992-12-16 Asahi Chem Ind Co Ltd 6−置換アルコキシキノキサリン誘導体含有医薬組成物およびその製造法
SE508669C2 (sv) 1996-04-26 1998-10-26 Astra Ab Nytt förfarande
EP1634872A1 (en) * 2004-08-27 2006-03-15 Laboratorios Del Dr. Esteve, S.A. Pyrazole derivatives as sigma receptor inhibitors
US7696199B2 (en) * 2004-08-27 2010-04-13 Laboratorios Del Dr. Esteve, S.A. Sigma receptor inhibitors
RU2417987C2 (ru) * 2004-08-27 2011-05-10 Лабораторьос Дель Др.Эстеве, С.А. Ингибиторы сигма-рецептора
JPWO2009038112A1 (ja) 2007-09-21 2011-01-06 塩野義製薬株式会社 Npyy5受容体拮抗剤を含有する固形製剤
EP2116539A1 (en) * 2008-04-25 2009-11-11 Laboratorios Del. Dr. Esteve, S.A. 1-aryl-3-aminoalkoxy-pyrazoles as sigma ligands enhancing analgesic effects of opioids and attenuating the dependency thereof
EP2113501A1 (en) * 2008-04-25 2009-11-04 Laboratorios Del. Dr. Esteve, S.A. 5-Methyl-1-(naphthalen-2-YL)-1H-Pyrazoles useful as sigma receptor inhibitors
EP2292236A1 (en) * 2009-08-14 2011-03-09 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for the prevention or treatment of pain induced by chemotherapy
EP2361904A1 (en) 2010-02-04 2011-08-31 Laboratorios Del. Dr. Esteve, S.A. 4-[-2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride and crystalline forms thereof
EP2335688A1 (en) * 2009-11-25 2011-06-22 Laboratorios Del. Dr. Esteve, S.A. Pharmaceutical compositions comprising sigma receptor ligands
DK2503993T3 (en) * 2009-11-25 2016-08-22 Esteve Labor Dr Hydrochloridsalt af 4-[2-[[5-methyl-1-(2-naphthalenyl)-1H-pyrazol-3-yl]oxy]ethyl]-morpholin
SG182628A1 (en) * 2010-02-04 2012-08-30 Esteve Labor Dr 4-[-2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride polymorphs and solvates
EP2353598A1 (en) * 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for use in the prevention and/or treatment of postoperative pain
EP2426112A1 (en) 2010-08-09 2012-03-07 Laboratorios Del. Dr. Esteve, S.A. 4-[-2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride polymorphs and solvates
EP2388005A1 (en) * 2010-05-21 2011-11-23 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy
EP2415471A1 (en) * 2010-08-03 2012-02-08 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in opioid-induced hyperalgesia
EP2460519A1 (en) * 2010-12-03 2012-06-06 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in bone cancer pain

Also Published As

Publication number Publication date
EP2603495A1 (en) 2013-06-19
MA34512B1 (fr) 2013-09-02
HK1186468A1 (en) 2014-03-14
US9428462B2 (en) 2016-08-30
KR20130095751A (ko) 2013-08-28
US20130150575A1 (en) 2013-06-13
WO2012019984A1 (en) 2012-02-16
MX341711B (es) 2016-08-31
JP2013533298A (ja) 2013-08-22
ES2543429T3 (es) 2015-08-19
EP2426111A1 (en) 2012-03-07
AU2011288550A1 (en) 2013-02-21
CA2807855C (en) 2018-10-23
CN103052626A (zh) 2013-04-17
SG187745A1 (en) 2013-03-28
JP5899214B2 (ja) 2016-04-06
TW201219387A (en) 2012-05-16
CN103052626B (zh) 2017-06-06
BR112013002651A2 (pt) 2016-05-31
CO6670586A2 (es) 2013-05-15
MX2013001559A (es) 2013-03-07
RU2013110313A (ru) 2014-09-20
CA2807855A1 (en) 2012-02-16
PT2603495E (pt) 2015-08-28
EP2603495B1 (en) 2015-05-06

Similar Documents

Publication Publication Date Title
AR082608A1 (es) Formas solidas de clorhidrato de 4-[2-[[5-metil-1-(2-naftalenil)-1h-pirazol-3-il]oxi]etil]morfolina
CY1122266T1 (el) Ενωσεις 3-αμινοκυκλοαλκυλιου ως ror-gamma-t αναστολεις και χρησεις αυτων
MX2012000973A (es) Compuestos para la reduccion de produccion de beta- amiloide.
PH12014501277A1 (en) Kinase inhibitors
EA019744B9 (ru) Изотиазолилоксифениламидины и их применение для борьбы с фитопатогенными грибами и семенной материал, обработанный изотиазолилоксифениламидинами
PH12014502397B1 (en) Pesticidal compositions and processes related thereto
BR112015000399A2 (pt) derivados de pirazolil pirimidina
EA201290097A1 (ru) Спиртовые композиции, имеющие пониженный риск возникновения ацетальдегидемии
TN2011000291A1 (en) Purine compounds
EA201270824A1 (ru) Соединения для уменьшения продукции бета-амилоида
PH12014501278A1 (en) Kinase inhibitors
RS53617B1 (en) NEW UNITS USEFUL FOR TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES
EA200802324A1 (ru) Новая форма введения рацекадотрила
MY174747A (en) Bace1 inhibitors
WO2009124962A3 (en) Sulfonamides
EA201171339A1 (ru) Способ снижения внутриглазного давления у людей
EP2655599A4 (en) HYDROGENOTROPIC PRODUCTION AND ORIENTED TO THE CALVIN CYCLE OF BUTANOL AND ASSOCIATED UPPER ALCOHOLS
MX2013008699A (es) Compuestos para reducir la produccion de beta-amiloide.
IN2014CN00981A (es)
MX2013002620A (es) Novedosas n-hidroxi-benzamidas para el tratamiento del cancer.
EA201101207A1 (ru) Применение антагонистов рецептора nk
MX2016003533A (es) Tripeptidos antiinflamatorios.
WO2014160177A3 (en) Quinazoline inhibitors of pi3k
EA201390757A1 (ru) БЕНЗОКСАЗЕПИНЫ КАК ИНГИБИТОРЫ PI3K/mTOR И СПОСОБЫ ИХ ИСПОЛЬЗОВАНИЯ И ПРОИЗВОДСТВА
MX2015007862A (es) Derivado de amida del acido cinamico.

Legal Events

Date Code Title Description
FB Suspension of granting procedure